Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

被引：0
作者：
Laura Ordoñez-Boschetti
Roberto Rey
Ana Cruz
Arijit Sinha
Tracy Reynolds
Nadina Frider
Regina Alvarenga
机构：
[1] Consultorio de Medicina Especializada del Sector Privado,
[2] Instituto Argentino de Investigación Neurológica,undefined
[3] Centro de Investigaciones Médicas Hospital Nacional Alberto Sabogal Sologuren,undefined
[4] Novartis Healthcare Pvt. Ltd.,undefined
[5] Novartis Pharma AG,undefined
[6] Novartis LAtinAmerica and Canada Region,undefined
[7] MS Hospital Da Lagoa,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Fingolimod; First-dose observations; FIRST LATAM; Latin American; Relapsing-remitting multiple sclerosis; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：626 / 635
页数：9
相关论文
共 49 条
[1]  
Compston A(2002)Multiple sclerosis Lancet 359 1221-1231
[2]  
Coles A(2008)MS in Latin America Int MS J 15 3-5
[3]  
Correale J(2008)MS in Latin America Int MS J. 15 6-11
[4]  
Luetic G(2013)Prevalence and clinical features of multiple sclerosis in Latin America Clin Neurol Neurosurg 115 381-387
[5]  
Ojeda E(2011)Multiple sclerosis in Hispanics: a study of clinical disease expression Mult Scler 17 1010-1016
[6]  
Diaz-Cortes D(2006)Multiple sclerosis in Latin America Neuroepidemiology 26 1-3
[7]  
Rosales D(2014)Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization J Neurol Sci 339 196-206
[8]  
Duarte-Rey C(2006)Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 1124-1140
[9]  
Anaya JM(2014)Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 545-556
[10]  
Rojas-Villarraga A(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
12345